- Home
- RPRX vs EXPD Comparison
RPRX vs EXPD Comparison
Compare RPRX & EXPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- EXPD
- Stock Information
- Founded
- RPRX 1996
- EXPD 1979
- Country
- RPRX United States
- EXPD United States
- Employees
- RPRX N/A
- EXPD N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- EXPD Oil Refining/Marketing
- Sector
- RPRX Health Care
- EXPD Consumer Discretionary
- Exchange
- RPRX Nasdaq
- EXPD Nasdaq
- Market Cap
- RPRX 16.2B
- EXPD 16.3B
- IPO Year
- RPRX 2020
- EXPD N/A
- Fundamental
- Price
- RPRX $39.45
- EXPD $139.91
- Analyst Decision
- RPRX Strong Buy
- EXPD Hold
- Analyst Count
- RPRX 3
- EXPD 10
- Target Price
- RPRX $46.00
- EXPD $129.22
- AVG Volume (30 Days)
- RPRX 3.9M
- EXPD 1.7M
- Earning Date
- RPRX 11-05-2025
- EXPD 11-04-2025
- Dividend Yield
- RPRX 2.23%
- EXPD 1.10%
- EPS Growth
- RPRX N/A
- EXPD 20.10
- EPS
- RPRX 1.75
- EXPD 6.15
- Revenue
- RPRX $2,349,844,000.00
- EXPD $11,167,760,000.00
- Revenue This Year
- RPRX $36.16
- EXPD $3.06
- Revenue Next Year
- RPRX $2.04
- EXPD N/A
- P/E Ratio
- RPRX $22.53
- EXPD $22.76
- Revenue Growth
- RPRX 3.70
- EXPD 12.54
- 52 Week Low
- RPRX $24.05
- EXPD $100.47
- 52 Week High
- RPRX $41.24
- EXPD $143.02
- Technical
- Relative Strength Index (RSI)
- RPRX 60.31
- EXPD 66.83
- Support Level
- RPRX $38.82
- EXPD $137.30
- Resistance Level
- RPRX $40.01
- EXPD $142.09
- Average True Range (ATR)
- RPRX 1.19
- EXPD 4.12
- MACD
- RPRX 0.05
- EXPD 0.96
- Stochastic Oscillator
- RPRX 66.81
- EXPD 87.52
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About EXPD Expeditors International of Washington Inc.
Based in the US, Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. Its offers freight consolidation and forwarding, customs brokerage, warehousing and distribution, purchase order management, vendor consolidation, and numerous other value-added logistics services. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. Expeditors derives around 35% of consolidated gross revenue from airfreight, 30% from ocean freight, and 36% from customs brokerage and other services.